全文获取类型
收费全文 | 445篇 |
免费 | 28篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 27篇 |
妇产科学 | 3篇 |
基础医学 | 41篇 |
口腔科学 | 2篇 |
临床医学 | 24篇 |
内科学 | 123篇 |
皮肤病学 | 6篇 |
神经病学 | 20篇 |
特种医学 | 25篇 |
外科学 | 130篇 |
综合类 | 4篇 |
预防医学 | 10篇 |
药学 | 50篇 |
肿瘤学 | 9篇 |
出版年
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 5篇 |
2016年 | 7篇 |
2015年 | 6篇 |
2014年 | 13篇 |
2013年 | 28篇 |
2012年 | 17篇 |
2011年 | 21篇 |
2010年 | 7篇 |
2009年 | 5篇 |
2008年 | 19篇 |
2007年 | 19篇 |
2006年 | 34篇 |
2005年 | 24篇 |
2004年 | 18篇 |
2003年 | 22篇 |
2002年 | 31篇 |
2001年 | 21篇 |
2000年 | 22篇 |
1999年 | 15篇 |
1998年 | 8篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 11篇 |
1994年 | 8篇 |
1993年 | 13篇 |
1992年 | 8篇 |
1991年 | 5篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 11篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 6篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1967年 | 1篇 |
1963年 | 1篇 |
1954年 | 1篇 |
排序方式: 共有474条查询结果,搜索用时 15 毫秒
1.
Fausto Biancari Giovanni Mariscalco Magnus Dalén Nicla Settembre Henryk Welp Andrea Perrotti Karsten Wiebe Enrico Leo Antonio Loforte Sidney Chocron Davide Pacini Tatu Juvonen L. Mikael Broman Dario Di Perna Hakeem Yusuff Chris Harvey Nicolas Mongardon Juan P. Maureira Antonio Fiore 《Journal of cardiothoracic and vascular anesthesia》2021,35(7):1999-2006
2.
对发展中国家改善用药的10点建议 总被引:2,自引:0,他引:2
WHO建议改善药品管理的工作要在国家药物政策保障之下.在许多国家,执行国家药物政策的机制是实施国家基本药物计划,其要点是强调公共领域的药品选择、采购、流通与使用的合理性.不适当的处方使医疗质量降低并导致资源浪费.本文以探讨在国家药物政策范畴内鼓励更合理地使用药品的问题为重点,在已有证据的基础上,详细阐明基本药物计划内容中的合理用药问题.本文评述了在发展中国家改善用药状况的有效策略及最新知识,并为决策者与管理者提出达到改善用药目标的建议. 相似文献
3.
4.
5.
Heikkinen Aki T. Friedlein Arno Matondo Mariette Hatley Oliver J. D. Petsalo Aleksanteri Juvonen Risto Galetin Aleksandra Rostami-Hodjegan Amin Aebersold Ruedi Lamerz Jens Dunkley Tom Cutler Paul Parrott Neil 《Pharmaceutical research》2015,32(1):74-90
Pharmaceutical Research - Beagle dogs are used to study oral pharmacokinetics and guide development of drug formulations for human use. Since mechanistic insight into species differences is needed... 相似文献
6.
Noriaki Moriyama Teemu Laakso Peter Raivio Sebastian Dahlbacka Eeva-Maija Kinnunen Tatu Juvonen Antti Valtola Annastiina Husso Maina P. Jalava Tuomas Ahvenvaara Tuomas Tauriainen Jarkko Piuhola Asta Lahtinen Matti Niemelä Timo Mäkikallio Marko Virtanen Pasi Maaranen Markku Eskola Mika Laine 《The Canadian journal of cardiology》2021,37(1):37-46
BackgroundThe data on acute kidney injury (AKI) in patients without chronic kidney disease (CKD) after transcatheter aortic valve replacement (TAVR) are limited. The study sought to compare the incidence of AKI and its impact on 5-year mortality after TAVR and surgical aortic valve replacement (SAVR) in patients without CKD.MethodsThis registry included data from 6463 consecutive patients who underwent TAVR or SAVR. CKD was defined as estimated glomerular filtration rate <60 mL/min/1.73 m2. AKI was defined according to the Kidney Disease Improving Global Outcomes criteria. For sensitivity analysis, propensity-score matching between TAVR and SAVR was performed.ResultsThe study included 4555 consecutive patients (TAVR, n = 1215 and SAVR, n = 3340) without CKD. Propensity-score matching identified 542 pairs. Patients who underwent TAVR had a significantly lower incidence of AKI in comparison to those who underwent SAVR (unmatched 4.7% vs 16.4%, P < 0.001, multivariable analysis: odds ratio, 0.29, 95% confidence interval [CI], 0.20-0.41; matched 5.9% vs 19.0%, P < 0.001). Patients with AKI had significantly increased 5-year mortality compared with those without AKI (unmatched 36.0% vs 19.1%, log-rank P < 0.001; matched 36.3% vs 24.0%, log-rank P < 0.001). The adjusted hazard ratios for 5-year mortality were 1.58 (95% CI, 1.20-2.08) for AKI grade 1, 3.27 (95% CI, 2.09-5.06) for grade 2, and 4.82 (95% CI, 2.93-8.04) for grade 3.ConclusionsTAVR in patients without CKD was associated with a significantly less frequent incidence of AKI compared with SAVR. AKI significantly increased the risk of 5-year mortality after either TAVR or SAVR, and increasing severity of AKI was incrementally associated with 5-year mortality. 相似文献
7.
Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study 总被引:2,自引:0,他引:2
Itälä M Geisler CH Kimby E Juvonen E Tjonnfjord G Karlsson K Remes K 《European journal of haematology》2002,69(3):129-134
OBJECTIVES: This prospective multicentre study was conducted to assess the efficacy of the monoclonal anti-CD20 antibody rituximab in patients with chronic lymphocytic leukaemia (CLL). Secondary objectives were defined as the tolerability and feasibility of rituximab in patients with CLL. METHODS: Twenty-four heavily pretreated patients with CLL were treated with a standard dose of 375 mg m-2 of rituximab given once weekly for four doses. RESULTS: The overall response rate was 35% and all the responses were partial as defined by the revised NCI criteria. In 17 (85%) of 20 patients with initially measurable peripheral lymph nodes the size of lymph nodes decreased by at least 50%, while an improvement of the bone marrow infiltration was observed only in two (11%) of 18 evaluable patients. The median duration of the overall response was 12.5 wk. Rituximab was relatively well tolerated. Although side-effects were common (75%) they were usually mild or moderate. There was only one grade 3 adverse event and no grade 4 events. CONCLUSIONS: Standard-dose rituximab has activity in heavily pretreated patients with CLL, although the response is mainly limited to the lymph nodes and of short duration. Since rituximab has in vitro synergism with chemotherapeutic agents and is well tolerated by CLL patients, it is reasonable to investigate rituximab in combination with other treatments. 相似文献
8.
Megakaryocytic colony formation by progenitor cells of 18 patients with polycythaemia vera, seven with secondary erythrocytosis and four with erythrocytosis of unexplained origin was studied in vitro by the methyl cellulose culture assay. Fourteen of the 18 patients with polycythaemia vera showed spontaneous megakaryocytic colony formation, i.e. colony growth with normal human plasma as the only source of colony stimulation. None of the patients with secondary erythrocytosis or erythrocytosis of unknown origin or of the normal controls grew colonies in the presence of normal human plasma only. When the plasma of a patient with aplastic anaemia was used instead of normal human plasma and phytohaemagglutinin stimulated leucocyte conditioned medium (PHA-LCM) was added to the culture medium, two of the patients with polycythaemia vera and one with secondary erythrocytosis formed slightly increased numbers of megakaryocytic colonies, while the rest of the patients showed normal colony formation. All of the patients with polycythaemia vera but none of those with secondary erythrocytosis or erythrocytosis of unknown origin showed spontaneous erythroid colony growth. The present study shows that most patients with polycythaemia vera form spontaneous megakaryocytic colonies in vitro. This phenomenon has recently also been demonstrated in essential thrombocythaemia and it is apparently analogous to spontaneous erythroid colony growth seen in all myeloproliferative disorders. 相似文献
9.
Bash RO; Crist WM; Shuster JJ; Link MP; Amylon M; Pullen J; Carroll AJ; Buchanan GR; Smith RG; Baer R 《Blood》1993,81(8):2110-2117
Alteration of the TAL1 locus is the most common nonrandom genetic defect in childhood T-cell acute lymphoblastic leukemia (T-ALL). To determine if rearrangements of the TAL1 proto-oncogene confer a distinct leukemic phenotype, we studied leukemic peripheral blood or bone marrow samples from 182 children with newly diagnosed T-ALL enrolled on Pediatric Oncology Group treatment protocols. Forty-eight (26%) of the samples had a local rearrangement of the TAL1 locus. Demographic and clinical features were compared for patient subgroups with and without TAL1 rearrangements. The only clinical correlates that were significantly associated with TAL1 gene rearrangements were higher white blood cell count (P = .017) and higher hemoglobin (P = .007) at diagnosis. Immunophenotypically, samples with altered TAL1 were more likely to be CD2+ (P = .001) and lack CD10 (cALLa) expression (P = .007) than those without the rearrangement. There was a trend toward improved event-free survival (EFS) in patients with TAL1 rearrangements (4-year EFS was 44% +/- 7% for patients without the rearrangements v 59% +/- 11% for those with rearrangements), but the difference was not significant (P = .34). The role of TAL1 in leukemogenesis has yet to be clearly defined, and the prognostic significance of TAL1 gene rearrangements in T-ALL deserves further study. 相似文献
10.
Histamine reduces boron neutron capture therapy‐induced mucositis in an oral precancer model 下载免费PDF全文